Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Douglas Lane & Associates LLC

Douglas Lane & Associates LLC decreased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 402,208 shares of the medical equipment provider’s stock after selling 14,085 shares during the period. Douglas Lane & Associates LLC owned about 0.20% of Zimmer Biomet worth $42,485,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in ZBH. Dunhill Financial LLC grew its stake in shares of Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares in the last quarter. Ashton Thomas Securities LLC acquired a new stake in shares of Zimmer Biomet in the 3rd quarter valued at about $28,000. Bangor Savings Bank acquired a new position in Zimmer Biomet during the third quarter worth approximately $31,000. Brooklyn Investment Group purchased a new position in shares of Zimmer Biomet during the third quarter worth approximately $35,000. Finally, Quarry LP purchased a new stake in Zimmer Biomet in the 2nd quarter valued at $53,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Down 1.8 %

NYSE ZBH traded down $1.90 during trading hours on Wednesday, reaching $101.23. 1,014,869 shares of the company’s stock were exchanged, compared to its average volume of 1,297,104. The company’s 50-day moving average is $108.36 and its two-hundred day moving average is $108.14. Zimmer Biomet Holdings, Inc. has a one year low of $100.67 and a one year high of $133.90. The company has a market capitalization of $20.15 billion, a price-to-earnings ratio of 19.25, a price-to-earnings-growth ratio of 1.96 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.74. The business had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. Zimmer Biomet’s revenue was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.65 earnings per share. On average, analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be given a dividend of $0.24 per share. The ex-dividend date is Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.95%. Zimmer Biomet’s payout ratio is presently 18.25%.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. BTIG Research reduced their target price on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research note on Thursday, October 3rd. Barclays reduced their target price on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a research report on Thursday, December 12th. Raymond James reduced their target price on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Wells Fargo & Company increased their price objective on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Finally, Truist Financial increased their price objective on shares of Zimmer Biomet from $117.00 to $118.00 and gave the company a “hold” rating in a research report on Wednesday, December 18th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $123.33.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.